Latest Taiho Pharmaceutical Stories
PRINCETON, N.J., Dec.
- Taiho Oncology Initiates Rolling NDA Submission for TAS-102 - PRINCETON, N.J., Oct.
TOKYO, July 23, 2014 /PRNewswire/ -- - Investment to Foster Early Biotech Start-ups - Taiho Pharmaceutical Co., Ltd.
- TAS-102 demonstrated a statistically significant improvement in overall survival and progression-free survival - BARCELONA, Spain and PRINCETON, N.J., June 28, 2014 /PRNewswire/
- Chief Commercial Officer, Tim Whitten, to lead commercialization effort - PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co.,
- Company Plans to Pursue Regulatory Submissions - TOKYO, May 12, 2014 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) and its division Taiho Oncology, Inc.
TOKYO, March 24, 2014 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd.